186 related articles for article (PubMed ID: 26130461)
21. Differential regulation of the alcohol dehydrogenase 1B (ADH1B) and ADH1C genes by DNA methylation and histone deacetylation.
Dannenberg LO; Chen HJ; Tian H; Edenberg HJ
Alcohol Clin Exp Res; 2006 Jun; 30(6):928-37. PubMed ID: 16737450
[TBL] [Abstract][Full Text] [Related]
22. Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer.
Kim NH; Sung HY; Choi EN; Lyu D; Choi HJ; Ju W; Ahn JH
Oncol Rep; 2014 May; 31(5):2139-46. PubMed ID: 24676393
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
[TBL] [Abstract][Full Text] [Related]
24. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
25. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy.
Frigola J; Muñoz M; Clark SJ; Moreno V; Capellà G; Peinado MA
Oncogene; 2005 Nov; 24(49):7320-6. PubMed ID: 16007128
[TBL] [Abstract][Full Text] [Related]
26. Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer.
Yanaihara N; Nishioka M; Kohno T; Otsuka A; Okamoto A; Ochiai K; Tanaka T; Yokota J
Int J Cancer; 2004 Oct; 112(1):150-4. PubMed ID: 15305387
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
[TBL] [Abstract][Full Text] [Related]
28. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Lee SH; Kim J; Kim WH; Lee YM
Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
[TBL] [Abstract][Full Text] [Related]
29. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
[TBL] [Abstract][Full Text] [Related]
30. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.
Su HY; Lai HC; Lin YW; Chou YC; Liu CY; Yu MH
Int J Cancer; 2009 Jan; 124(2):387-93. PubMed ID: 18942711
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin.
Lee SE; Kim SJ; Yoon HJ; Yu SY; Yang H; Jeong SI; Hwang SY; Park CS; Park YS
J Pineal Res; 2013 Jan; 54(1):80-8. PubMed ID: 22856590
[TBL] [Abstract][Full Text] [Related]
32. Aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma.
Baranova I; Kovarikova H; Laco J; Dvorak O; Sedlakova I; Palicka V; Chmelarova M
Cancer Biomark; 2018; 23(1):125-133. PubMed ID: 29991130
[TBL] [Abstract][Full Text] [Related]
33. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Byrnes J; Lum E; Kamalakaran S; Levine DA; Dimitrova N; Zhang MQ; Lucito R
PLoS One; 2011; 6(12):e28503. PubMed ID: 22174824
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic Biomarkers in Colorectal Cancer.
Verma M; Kumar V
Mol Diagn Ther; 2017 Apr; 21(2):153-165. PubMed ID: 27878475
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review).
Koukoura O; Spandidos DA; Daponte A; Sifakis S
Mol Med Rep; 2014 Jul; 10(1):3-9. PubMed ID: 24821107
[TBL] [Abstract][Full Text] [Related]
36. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies.
Eskander RN
Am Soc Clin Oncol Educ Book; 2018 May; 38():480-487. PubMed ID: 30231335
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.
Greville G; McCann A; Rudd PM; Saldova R
Epigenetics; 2016 Dec; 11(12):845-857. PubMed ID: 27689695
[TBL] [Abstract][Full Text] [Related]
38. SiRNA and epigenetic aberrations in ovarian cancer.
Mirzaei H; Yazdi F; Salehi R; Mirzaei HR
J Cancer Res Ther; 2016; 12(2):498-508. PubMed ID: 27461600
[TBL] [Abstract][Full Text] [Related]
39. Current data and future perspectives on DNA methylation in ovarian cancer (Review).
Fu M; Deng F; Chen J; Fu L; Lei J; Xu T; Chen Y; Zhou J; Gao Q; Ding H
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757340
[TBL] [Abstract][Full Text] [Related]
40. Integrated multiomic predictors for ovarian cancer survival.
Fu A; Chang HR; Zhang ZF
Carcinogenesis; 2018 Jul; 39(7):860-868. PubMed ID: 29897425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
